)
Edge11 Sep 2026
Texas Pacific Land Corporation: Keeper of the Permian Basin
Land once granted to a failed 19th-century railroad now generates royalties for Texas Pacific Land Corporation across the Permian Basin.
AlzeCure Pharma
AlzeCure Pharma (ALZCUR) investor relations material
AlzeCure Pharma Investor update summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Investor update summary18 Sep, 2026
Strategic partnerships and collaborations
Secured two transformative out-licensing and collaboration deals with Eli Lilly and QuantumCell, totaling $3.2 billion in deal value, excluding royalties.
Entered collaboration and outlicensing agreements with Eli Lilly for the Alzstatin platform targeting Alzheimer's disease.
Signed a collaboration agreement with QuantumCell ApS for the NeuroRestore platform.
Received $22 million in upfront payments and completed a SEK 30 million rights issue, strengthening the cash position.
Ongoing collaborations with Eli Lilly and QuantumCell involve active tech transfer and program initiation.
Company focus and development
Business model centers on identifying targets, developing small molecules in-house, and out-licensing after clinical development.
Focuses on developing small-molecule drug candidates for CNS diseases, especially Alzheimer's and pain.
Advances multiple drug candidates in parallel across three platforms: NeuroRestore, Alzstatin, and Painless.
Pipeline and therapeutic focus
Focused on Alzheimer's and pain, addressing large and growing unmet medical needs.
Alzstatin platform, a gamma-secretase modulator for Alzheimer's, out-licensed to Eli Lilly.
NeuroRestore platform, targeting learning, memory, and depression, out-licensed to QuantumCell.
Painless platform includes ACD137 for osteoarthritis and ACD440 for neuropathic pain and erythromelalgia.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from AlzeCure Pharma
- Major out-licensing deals and clinical advances drive strong growth and validation in 2026.ALZCUR
Pareto Securities Capital Market Days presentation - Landmark licensing deals and strong clinical progress fueled a dramatic financial turnaround.ALZCURQ2 2026
- Advancing innovative Alzheimer's and pain therapies with a robust, grant-backed clinical pipeline.ALZCURABGSC Investor Days
- ACD137 delivers potent, selective pain relief and joint protection, advancing toward clinical trials.ALZCURStudy update
- Operating loss widened as R&D accelerated, with key clinical advances and new financing secured.ALZCURQ1 2026
- Secured major grant, achieved key regulatory milestones, and strengthened financial position.ALZCURQ4 2025
- Oversubscribed rights issue and FDA orphan status drive R&D progress despite ongoing losses.ALZCURQ3 2025
- ACD 440 advances as a first-in-class orphan drug for erythromelalgia with strong clinical results.ALZCURStatus Update
- ACD440 gel delivers targeted, effective neuropathic pain relief with strong safety and market potential.ALZCURStudy Update
Next AlzeCure Pharma earnings date
Swiss Nordic Bio 2026 presentation1 Oct, 2026
AlzeCure Pharma
Next AlzeCure Pharma earnings date
Swiss Nordic Bio 2026 presentation1 Oct, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage